Work

689TiP NRG Oncology’s GU007 (NADIR): A randomized phase II trial of niraparib with standard combination androgen deprivation therapy (ADT) and radiotherapy (RT) in high-risk prostate cancer (PC) (with initial phase I)

Year: 2020

Type: article

Source: Annals of Oncology

DOI: 10.1016/j.annonc.2020.08.2083

Authors: Z. Zumsteg, T. Karrison, M.D. Michaelson, P. Tran, R. Kudchadker, F. Feng

Institutions: Cedars-Sinai Medical Center, University of Chicago, Harvard University, Massachusetts General Hospital, Johns Hopkins University, The University of Texas MD Anderson Cancer Center, University of California, San Francisco

Language: English

Topic: PARP inhibition in cancer therapy

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

OpenAlex ID: W3088685802

FWCI: 0.321

Cites:

Cited by: 7

Related to: 10